Zastosowanie technologii macierzy ekspresyjnych, proteomicznych oraz tkankowych w badaniach nad onkogenezą u ssaków

• Autorzy: Kempisty B. , Zawierucha P. , Piotrowska H. , Nowicki M.

Warianty tytułu

EN

Technology based on expression microarrays, proteomic microarrays and tissue microarrays in mammalian oncogenesis research

• Języki publikacji: PL

Abstrakty

EN

Technological progress in the past few years has made it possible to apply techniques based on microarrays in the analyses of cancerogenesis. These techniques can be divided into several groups according to the scale of research: (1) gene expression analysis, (2) protein analysis, (3) tissue research. The gene expression analysis makes it possible to compare the levels of gene activity in cancer tissue with those in reference tissue, and to evaluate the progression of cancer and its reaction to treatment. The analysis of proteins provides information on their functional and structural characteristics, and throws light on the protein-ligand interaction and the relations between the presence or absence of certain proteins in specific physiological states. Tissue microarrays are applied to analyze cancer markers and to identify DNA, RNA and proteins. This article presents selected aspects of microarray research and discusses the molecular aspects of cancerogenesis in dogs, referring to several types of genes associated with cancers.

Słowa kluczowe

PL

ssaki; onkogeneza; mikromacierze; macierze bialkowe; macierze tkankowe; bialko RAD51; bialko BRCA1; bialko BRCA2; gen COX2; bialko Tp53; bialko RCAS1; ekspresja genow

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2011
• Tom: 67
• Numer: 11
• Opis fizyczny: s.720-723,bibliogr.

Twórcy

autor

Kempisty B.

• Katedra i Zakład Histologii i Embriologii, Wydział Lekarski II, Uniwersytet Medyczny w Poznaniu, ul.Święcickiego 6, 60-781 Poznań

autor

Zawierucha P.

autor

Piotrowska H.

autor

Nowicki M.

Bibliografia

• 1.Brown C. J., Lain S., Verma C. S., Fersht A. R., Lane D. P.: Awaking guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9, 862-873.
• 2.Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T. C., Willi N., Mihatsch M. J., Sauter G., Kallioniemi O. P.: Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hubridization on tissue microarrays. Cancer Res. 1999, 59, 803-806.
• 3.Bullock A. N., Fersht A. R.: Rescuing the function of mutant p53. Nat. Rev. Cancer 2001, 1, 68-76.
• 4.Camp R. L., Cherette L. A., Rimm D. L.: Validation of tissue microarray technology in brest carcinoma. Lab. Invest. 2000, 80, 1943-1949.
• 5.Chaib H., Rubin M. A., Mucci N. R., Taylor J. M. G., Day M. L., Rhim J. S., Macoska J. A.: Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors. Cancer Res. 2001, 61, 2390-2394.
• 6.Chu L. L., Rutteman G. R., Kong J. M., Ghahremani M., Schmeing M., Misdorp W., van Garderen E., Pelletier J.: Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res. Treat. 1998, 50, 11-25.
• 7.Cotchin F.: Further observations on neoplasis in dogs with particular reference to site of origin and malignancy. Br. Vet. J. 1954, 110, 218.
• 8.Doré M., Lanthier I., Sirois J.: Cyclooxygenase-2 expression in canine mammary tumors. Vet. Pathol. 2003, 40, 207-212.
• 9.Dutsch-Wicherek M.: RCAS1, MT, and Vimetin as Potential Markers of Tumor Microenviroment Remodeling. Am. J. of Reprod. Immunol. 2010, 63, 181-188.
• 10.Dutsch-Wicherek M., Wicherek L.: The association of RCAS1 serum concentration with the reversibility or irreversibility of the proces sof immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am. J. Reprod. Immunol. 2008, 59, 266-275.
• 11.Easton D. F., Deffenbaugh A. M., Pruss D., Frye C., Wenstrup R. J., Allen-Brady K., Tavtigian S. V., Monteiro A. N., Iversen E. S., Couch F. J., Goldgar D. E.: A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet. 2007, 81, 873-883.
• 12.Heller D. A., Clifford C. A., Goldschmidt M. H., Holt D. E., Shofer F. S., Smith A., Sorenmo K. U.: Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Vet. Pathol. 2005, 42, 776-780.
• 13.Horvath L., Henshall S.: The application of tissue microarrays to cancer research. Pathology 2001, 33, 125-129.
• 14.Kleiter M., Malarkey D. E., Ruslander D. E., Thrall D. E.: Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Vet. Radiol. Ultrasound 2004, 45, 255-260.
• 15.Klopfleisch R., Schütze M., Gruber A. D.: RAD51 protein expression is increased in canine mammary carcinomas. Vet. Pathol. 2010, 47, 98-101.
• 16.Kodadek T.: Protein microarrays: Prospects and problems. Chem. Biol. 2001, 5, 40-45.
• 17.Lassus H., Laitinen M. P., Anttonen M., Heikinheimo M., Aaltonen L. A., Ritvos O., Butzow R.: Comparison of serous and mucinous ovarian carcinomas: Distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4. Lab. Invest. 2001, 81, 517-526.
• 18.Levine A. J., Oren M.: The first 30 years of p53: groing ever more complex. Nature Rev. 2009, 9, 749-758.
• 19.Matsushima T., Nakashima M., Oshima K., Abe Y., Nishimura J., Nawata H., Watanabe T., Muta K.: Rreceptor binding cancer antigen expresses on SiSo cells, a novel regulator of apoptosis erythroid progenitor cells. Blood 2001, 15, 131-321.
• 20.Miettinen H. E., Jarvinen T. A., Kellner U., Kauraniemi P., Parwaresch R., Rantala I., Kalimo H., Paljärvi L., Isola J., Haapasalo H.: High topoisomerase IIalpha expression associates with high proliferation rate and poor prognosis in oligodendriogliomas. Neuropathol. Appl. Neurobiol. 2000, 26, 504-512.
• 21.Moulton J. E.: Tumors of the mammary gland, [w:] Moulton J. E. (ed): Tumors in Domestic Animals. University of California Press, Berkley 1990, 3, 518-552.
• 22.Nakashima M., Sonoda K., Watanabe T.: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat. Med. 1999, 5, 928-942.
• 23.Nocito A., Bubendorf L., Tinner E. M., Süess K., Wagner U., Forster T., Kononen J., Fijan A., Bruderer J., Schmid U., Ackermann D., Maurer R., Alund G., Knönagel H., Rist M., Anabitarte M., Hering F., Hardmeier T., Schoenenberger A. J., Flury R., Jäger P., Fehr J. L., Schraml P., Moch H., Mihatsch M. J., Gasser T., Sauter G.: Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J. Pathol. 2001, 194, 349-357.
• 24.Paweletz C. P., Charboneau L., Bichsel V. E., Simone N. L., Chen T., Gillespie J. W., Emmert-Buck M. R., Roth M. J., Petricoin III E. F., Liotta L. A.: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20, 1981-1989.
• 25.Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S. V., Hainaut P., Olivier M.: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor henotype: lesons from recent development in the ARC TP53 database. Hum. Mutat. 2007, 28, 622-629.
• 26.Rihn B. H., Mohr S., McDowell S. A., Binet S., Loubinoux J., Galateau F., Keith G., Leikauf G. D.: Differential gene expression in mesothelioma. FEBS Lett. 2000, 480, 495-510.
• 27.Rousseau J., Tętu B., Caron D., Malenfant P., Cattaruzzi P., Audette M., Doillon C., Tremblay J. P., Guérette B.: RCAS1 is associated with ductal breast cancer progression. Biochem. Biophys. Res. Commun. 2002, 293, 1544-1549.
• 28.Schraml P., Kononen J., Bubendorf L., Moch H., Bissig H., Nocito A., Mihatsch M. J., Kallioniemi O. P., Sauter G.: Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer. Res. 1999, 5, 1966-1975.
• 29.Sonoda K., Miyamoto S., Akashima M., Wake N.: The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front. Biosci. 2008, 13, 1106-1116.
• 30.Sonoda K., Miyamoto S., Hirakawa T., Yagi H., Yotsumoto F., Nakashima M., Watanabe T., Nakano H.: Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol. Oncol. 2006, 103, 924-931.
• 31.Sonoda K., Miyamoto S., Hirakawa T., Yagi H., Yotsumoto F., Nakashima M., Watanabe T., Nakano H.: Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol. Oncol. 2005, 99, 189-198.
• 32.Sonoda K., Nakashima M., Kaku T., Kamura T., Nakano H., Watanabe T.: A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996, 77, 1501-1509.
• 33.Stratowa C., Loffler G., Lichter P., Stilgenbauer S., Haberl P., Schweifer N., Döhner H., Wilgenbus K. K.: CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int. J. Cancer 2001, 91, 474-480.
• 34.Wicherek L.: Alternations in RCAS1 serum concentration levels during menstrual cycle in patients with uterine leiomyoma and lack of analogical changes in adenomyosis. Gynecol. Obstet. Invest. 2009, 67, 195-201.
• 35.Wicherek L.: Alternations in RCAS1 serum concentration levels during the normal menstrual cycle and lad lack of analogical changes in ovarian endometriosis. Am. J. Reprod. Immunol. 2008, 59, 535-544.
• 36.Xu R., Gan X., Fang Y., Zheng S., Dong Q.: A simple, rapid, and sensitive integrated protein microarray for simultaneous detection of multiple antigens and antibodies of five human hepatitis viruses (HBV, HCV, HDV, HEV, and HGV). Anal. Biochem. 2007, 362, 69-75.